Table 3.
Management and sequelae of 145 cases of temporal bone osteoradionecrosis (TBORN).
| Outcome | Temporal bonesa N = 145 (%) |
|---|---|
|
| |
| Total conservatively managed | 117 (81) |
| Total surgically managed | 28 (19) |
| Received HBO | 27 (19) |
| Received PENTO | 10 (7) |
| Ablative surgeryb | |
| LTBR | 16 (57) |
| CWD with MO | 4 (14) |
| Canalplasty | 3 (11) |
| Labyrinthectomy | 2 (7) |
| Mastoidectomy without MO | 2 (7) |
| STBR | 1 (4) |
| Reconstructive surgeryc | |
| Temporalis muscle flap | 11 (48) |
| Free flap | 12 (52) |
| Hearing rehabilitation | |
| OIHA | 17 (12) |
| CI | 1 (1) |
| Mean length of follow up ± SD (range), y | 3.7 ± 3.5 (< 1–14) |
| Associations | |
| Chronic otorrhea | 17 (12) |
| Non-healing TM perforation | 16 (11) |
| Cholesteatoma | 10 (7) |
| Complications | |
| Temporal bone osteomyelitis | 10 (7) |
| Wound infection | 8 (6) |
| Facial palsy | 5 (3) |
| Profound SNHL | 5 (3) |
| Carotid rupture | 3 (2) |
| Dead at last follow-up | 40 (28) |
| Attributed to TBORN | 1 (1) |
a
Unless otherwise indicated.
b
No. (%) of those surgically managed (N = 28).
c
No. (%) of those surgically managed with additional reconstructive surgery (N = 23).
Abbreviations: HBO, hyperbaric oxygen; PENTO, pentoxifylline and tocopherol; LTBR, lateral temporal bone resection; CWD, canal wall down tympanomastoidectomy; MO, mastoid obliteration; STBR, subtotal temporal bone resection; OIHA, osseointegrated hearing aid; CI, cochlear implant; TM, tympanic membrane; SNHL, sensorineural hearing loss.